Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study

Archives of General Psychiatry

Volumn 64, Issue 9, 2007, Pages 1069-1077

  Ray, Lara A ^a,b   Hutchison, Kent E ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; NAUSEA; PROFILE OF MOOD STATES; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; BEHAVIOR, ADDICTIVE; BREATH TESTS; DOUBLE-BLIND METHOD; EMOTIONS; ETHANOL; FEMALE; GENOTYPE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PHARMACOGENETICS; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, OPIOID, MU; REWARD; VARIATION (GENETICS);

EID: 34548458513     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.64.9.1069     Document Type: Article

References (73)

1. Erickson CK. Review of neurotransmitters and their role in alcoholism treatment. Alcohol Alcohol. 1996;31:5-11.
2. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997;129(2):99-111.
3. Kreek MJ. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochem Res. 1996;21(11):1469-1488.
4. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2003;12:S3-S11.
5. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27(7):1142-1149.
6. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25(11):1634-1647.
7. Rubio G, Manzanares J, Lopez-Munoz F, Alamo C, Ponce G, Jimenez-Arriero MA, Palomo T. Naltrexone improves outcome of a controlled drinking program. J Subst Abuse Treat. 2002;23(4):361-366.
8. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758-1764.
9. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381-1387.
10. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebocontrolled study. Arch Gen Psychiatry. 2003;60(1):92-99.
11. Heinälä P, Alho H, Kiianmaa K, Lonnqvist J, Kouppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287-292.
12. Latt NC, Jurd S, Houseman J, Wultzke SE. Naltrexone in alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530-534.
13. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876-880.
14. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49(11):881-887.
15. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587-593.
16. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565-1573.
17. Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996;20(4):732-739.
18. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donavan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
19. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs nefazedone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology. 2000;22(5):493-503.
20. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004;28(11):1710-1717.
21. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739.
22. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004;173(1-2):32-40.
23. Drobes DJ, Anton RF, Thomas SE, Vornin K. Effects of naltrexone and namefene on subjective response to alcohol among non-treatment seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004;28(9):1362-1370.
24. King AC, Volpicelli JR, Frazer A, O'Brien CP. Effects of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl). 1997;129(1):15-22.
25. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA. Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology. 2001;25(4):537-547.
26. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10(3):258-268.
27. Swift RM, Whelihan W, Kusnetsov O, Buongiorno G, Hsuing H. Naltrexoneinduced alterations in human ethanol intoxication. Am J Psychiatry. 1994;151(10):1463-1467.
28. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effects of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152(4):613-615.
29. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546-1552.
30. Goldman D, Oroszi G, O'Malley S, Anton R. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl. 2005;(15):56-64.
31. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95(16):9608-9613.
32. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280(38):32618-32624.
33. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the μ -opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet. 2003;118(1):60-65.
34. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A. The μ-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology. 2001;26(1):106-114.
35. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997;2(6):490-494.
36. Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA Jr, O'Brien CP, Berrettini WH, Grice DE. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet. 2003;13(3):169-173.
37. Franke P, Wang T, Nöthen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W. Nonreplication of association between μ-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet. 2001;105(1):114-119.
38. Gelernter J, Kranzler H, Cubells J. Genetics of two μ opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry. 1999;4(5):476-483.
39. Kranzler HR, Gelernter J, O'Malley S, Hernandez-Avila CA, Kaufman D. Association of alcohol or other drug dependence with alleles of the μ opioid receptor gene (OPRM1). Alcohol Clin Exp Res. 1998;22(6):1359-1362.
40. Loh W, Fann CS, Chang YT, Chang CJ, Cheng AT. Endogenous opioid receptor genes and alcohol dependence among Taiwanese men. Alcohol Clin Exp Res. 2004;28(1):15-19.
41. Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet. 2003;120(1):97-108.
42. Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M. A functional polymorphism within the μ-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry. 2002;7(2):224-228.
43. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G. Sequence variations in the μ -opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002;19(4):459-460.
44. Tan EC, Tan C, Karupathivan U, Yap EP. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport. 2003;14(4):569-572.
45. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, Hughes P, Duara R, Mullan M. Association of a functional μ-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet. 1999;88(5):458-461.
46. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83(3):262-268.
47. Ray LA, Hutchison KE. A polymorphism of the μ-opioid receptor gene and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789-1795.
48. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636-645.
49. Hines L, Ray LA, Hutchison KE, Tabakoff B. Alcoholism: the dissection for endophenotypes [dialogues]. Clin Neurosci. 2005;7:153-163.
50. Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res. 1997;21(4):613-619.
51. Li TK, Yin S, Crabb DW, O'Connor S, Ramchandani VA. Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res. 2001;25(1):136-144.
52. O'Connor S, Morzorati S, Christian J, Li T. Clamping breath alcohol concentration reduces experimental variance: application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res. 1998;22(1):202-210.
53. Ramchandani VA, Bolane J, Li TK, O'Connor S. A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res. 1999;23(4):617-623.
54. Ray LA, McGeary J, Marshall E, Hutchison KE. Risk factors for alcohol misuse: examining heart rate reactivity to alcohol, alcohol sensitivity, and personality constructs. Addict Behav. 2006;31(11):1959-1973.
55. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20(8):1412-1417.
56. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R. DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behav Genet. 1997;27(3):251-257.
57. Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA, Rebbeck TR. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect. 1999;107(7):517-520.
58. Lench N, Stanier P, Williamson R. Simple non-invasive method to obtain DNA for gene analysis. Lancet. 1988;1(8599):1356-1358.
59. Spitz E, Moutier R, Reed T, Busnel MC, Marchaland C, Roubertoux PL, Carlier M. Comparative diagnoses of twin zygosity by SSLP variant analysis, questionnaire, and dermatoglyphic analysis. Behav Genet. 1996;26(1):55-63.
60. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999;14(5-6):143-149.
61. Ray LA, Meskew-Stacer S, Hutchison KE. The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. J Stud Alcohol Drugs. 2007;68(3):379-384.
62. Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM. Interrater agreement and interclass reliability measure of SAFTEE in psychopharmacologic clinical trials. Psychopharmacol Bull. 1986;22(2):382-388.
63. Levine J, Schooler N. SAFTEE: a technique for systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-381.
64. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19(3):600-606.
65. MacKillop J. Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res. 2006;30(8):1315-1321.
66. Schuckit MA. Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry. 1984;41(9):879-884.
67. Erblich J, Earleywine M. Distraction does not impair memory during intoxication: support for the attention-allocation model. J Stud Alcohol. 1995;56(4):444-448.
68. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM. Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res. 1993;17(1):140-146.
69. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, CA: Educational & Industrial Testing Service; 1971.
70. 2 from contingency tables and the calculation of P. J R Stat Soc [Ser A]. 1922;85:87-94.
71. O'Malley SS, Krishnan-Sarin S, Farren C, O'Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence of opioid-mediated effects. J Clin Psychopharmacol. 2000;20(1):69-76.
72. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25(9):1335-1341.
73. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544-552.